10-Q: Annexon Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

Annexon Inc. reports a net loss of $34.8 million for the third quarter of 2024, while highlighting progress in its clinical programs and financial position.

Summary

• Annexon Inc., a clinical-stage biopharmaceutical company, reported a net loss of $34.8 million for the three months ended September 30, 2024, compared to a net loss of $32.5 million for the same period in 2023.
• The company's research and development expenses increased to $30.1 million for the quarter, up from $27.9 million in the prior year.
• General and administrative expenses also rose to $9.3 million from $6.9 million year-over-year.
• Interest and other income, net, increased significantly to $4.6 million, compared to $2.3 million in the third quarter of 2023, due to higher cash and investment balances and favorable interest rates.
• For the nine months ended September 30, 2024, the net loss was $89.6 million, compared to $106.3 million for the same period in 2023.
• The company's cash and cash equivalents and short-term investments totaled $340.1 million as of September 30, 2024.
• Annexon believes its current cash resources will fund operations into the second half of 2026.
• The company is advancing its lead candidate, ANX005, for Guillain-Barr Syndrome (GBS), with a planned BLA submission in the first half of 2025.
• Patient dosing has begun in the global pivotal Phase 3 ARCHER II trial for ANX007 in Geographic Atrophy (GA), with topline data expected in the second half of 2026.
• Initial data from the proof-of-concept study for ANX1502 in cold agglutinin disease (CAD) is expected in the first quarter of 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company is making progress on its clinical programs and has a solid cash position, it continues to incur significant losses and faces various risks. The sentiment is cautiously optimistic, reflecting the potential of the pipeline but also the challenges ahead.

Positives

• The company's cash position remains strong at $340.1 million, providing a runway into the second half of 2026.
• The company is making progress on its key clinical programs, including ANX005 in GBS, ANX007 in GA, and ANX1502 in autoimmune diseases.
• Interest income has increased due to higher cash balances and favorable interest rates.
• The company has initiated patient dosing in the pivotal Phase 3 ARCHER II trial for ANX007 in GA.
• The company has completed a bridging study from liquid to a tablet formulation of ANX1502.

Negatives

• The company continues to incur significant net losses, with a $34.8 million loss for the third quarter of 2024.
• Research and development expenses have increased, reflecting ongoing investment in clinical programs.
• General and administrative expenses have also increased, indicating higher operational costs.
• The company has an accumulated deficit of $662.1 million as of September 30, 2024.

Risks

• The company's future viability depends on its ability to achieve development and regulatory milestones and obtain additional funding.
• There are uncertainties associated with the company's ability to obtain additional equity or debt financing on favorable terms.
• The company may be forced to delay, reduce, or eliminate its research and development programs if it cannot secure sufficient funding.
• The company's product candidates are in early stages of clinical development, and there is no guarantee of regulatory approval or commercial success.
• The company relies on third-party suppliers for manufacturing, and any disruptions could affect its ability to conduct clinical trials or commercialize products.
• The company faces significant competition in the biopharmaceutical industry.
• The company's stock price has been volatile and could be volatile in the future.

Future Outlook

The company believes its existing cash and cash equivalents and short-term investments will enable it to fund operating expenses and capital expenditure requirements into the second half of 2026. The company plans to submit a BLA for ANX005 in GBS in the first half of 2025 and expects topline data from the ARCHER II trial for ANX007 in GA in the second half of 2026. Initial data from the ANX1502 proof-of-concept study in CAD is expected in the first quarter of 2025.

Management Comments

• Management projects that existing cash and cash equivalents and short-term investments will enable the Company to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements.
• Management expects to continue to incur losses and negative cash flows from operations for at least the next several years.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on novel complement medicines for inflammatory-related diseases. The company's approach of targeting C1q is a novel therapeutic approach. The company is competing with other companies developing treatments for autoimmune, neurodegenerative, and ophthalmological conditions. The company is also competing with companies that have already received FDA approval for treatments in the same indications.

Comparison to Industry Standards

• Annexon's cash burn rate is typical for a clinical-stage biotech company with multiple ongoing trials.
• The company's focus on complement inhibition aligns with a growing trend in the industry, but its specific approach of targeting C1q is unique.
• The company's timeline for BLA submission for ANX005 and Phase 3 data for ANX007 is consistent with industry timelines for similar programs.
• The company's financial position is relatively strong compared to other companies at a similar stage of development, with a cash runway into the second half of 2026.
• The company's reliance on third-party manufacturers is standard practice in the industry, but it introduces risks related to supply chain and quality control.
• The company's approach of using visual protection as the primary endpoint in the ARCHER II trial is a novel approach compared to other GA trials.

Related Party Transactions

• An entity related to one of the company's directors participated in the public offering in December 2023 and purchased 350,000 shares of common stock for an aggregate price of approximately $1.0 million.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may benefit from the company's growth and development.
• Patients may benefit from the development of new treatments for inflammatory-related diseases.
• Suppliers and creditors may be affected by the company's financial performance and ability to pay its obligations.

Next Steps

• The company plans to submit a BLA for ANX005 in GBS in the first half of 2025.
• The company will continue patient enrollment in the Phase 3 ARCHER II trial for ANX007 in GA, with topline data expected in the second half of 2026.
• The company will continue the proof-of-concept study for ANX1502 in CAD, with initial data expected in the first quarter of 2025.
• The company will continue to assess plans for a Phase 3 injection-controlled study, ARROW, for ANX007 in GA.

Key Dates

Keywords

Annexon, ANX005, ANX007, ANX1502, Guillain-Barr Syndrome, Geographic Atrophy, Cold Agglutinin Disease, Clinical Trials, Biopharmaceutical, Complement Pathway, C1q, Autoimmune, Neurodegeneration, Ophthalmology, BLA, Phase 3, R&D, Financial Results